| Business Summary | | Arena
Pharmaceuticals,
Inc.
has
developed
a
technology,
Constitutively
Activated
Receptor
Technology
(CART),
designed
to
identify
drug-like
compounds
more
efficiently
than
traditional
drug
discovery
techniques.
CART
allows
the
Company
to
develop
novel
biochemical
assays
to
discover
drug-like
compounds
that
target
G
protein-coupled
receptors
(GPCRs),
an
important
class
of
receptors.
Additionally,
CART
may
be
applicable
to
other
human
receptor
classes,
such
as
tyrosine
kinase
receptors
(TKRs),
as
well
as
to
non-human
receptors,
for
the
discovery
of
animal
therapeutics
and
agricultural
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ARNA
is
the
developer
of
CART,
a
technology
used
to
discover
chemical
compounds
that
act
on
a
class
of
drug
targets
called
G
protein-coupled
receptors.
For
the
six
months
ended
6/30/01,
revenues
totaled
$8.7
million,
up
from
$1.3
million.
Net
loss
applicable
to
Comm.
fell
93%
to
$2.1
million.
Revenues
reflect
research
funding,
milestone
payment,
and
technology
access
fees
in
collaborations
with
Eli
Lilly
and
Taisho.
Lower
losses
also
reflect
the
absence
of
a
$22.4
million
preferred
stock
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Jack Lief, 55 Pres,
CEO, Director | $322K | $20K | Joseph Mooney, 53 CFO | -- | -- | Richard Burgoon, Jr., 39 Sr.
VP, Operations, Gen. Counsel and Sec. | 233K | 45K | Robert Hoffman, 35 VP-Fin. | -- | -- | Dominic Behan, Ph.D., 37 VP,
Research | 255K | 20K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|